Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 3/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40920 | 0.93 | MC4R (0.51) | MC4RADRA1AKCNH2HRH3POLB | |
| SCHEMBL42062 | 0.92 | MC4R (0.51) | MC4RADRA1AKCNH2HRH3POLB | |
| SCHEMBL47093 | 0.85 | MC4R (0.69) | MC4R | |
| SCHEMBL15078344 | 0.82 | MC4R (0.47) | MC4RADRA1AKCNH2HRH3POLB | |
| SCHEMBL42326 | 0.77 | MC4R (0.49) | MC4RADRA1AKCNH2HRH3POLB | |
| SCHEMBL15078345 | 0.77 | MC4R (0.47) | MC4RADRA1AKCNH2HRH3POLB | |
| SCHEMBL41414 | 0.76 | MC4R (0.46) | MC4RADRA1AKCNH2HRH3POLB | |
| SCHEMBL15078513 | 0.75 | MC4R (0.59) | MC4R | |
| SCHEMBL47254 | 0.75 | ADRA1A (0.46) | MC4RADRA1AKCNH2HRH3AVPR1B | |
| SCHEMBL45263 | 0.75 | SIGMAR1 (0.49) | MC4RADRA1AKCNH2HRH3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | UNIVERSITE DE MONTREAL (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20130165426-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal (CA) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165426-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MC4R, MC5R, MC1R | MC4R 1/4885ADRA1A 165/4885KCNH2 1124/4885 |
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MC4R, MC5R, MC1R | MC4R 1/4885ADRA1A 178/4885KCNH2 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.